Gennex Laboratories Ltd (531739)

Gennex Laboratories Ltd has informed the exchanges that its Board of Directors will meet on Friday, September 04, 2026. The primary agenda includes finalizing the date, time, and venue for the 41st Annual General Meeting (AGM) for FY26. The board will also consider the appointment of a scrutinizer for the AGM process. This is a routine administrative compliance meeting with no financial or operational impact.

• Board meeting scheduled for Friday, September 04, 2026 at 04:00 PM
• Agenda includes deciding the conduct and schedule of the 41st AGM for FY26
• Appointment of scrutinizer for the 41st AGM to be considered

Gennex Laboratories reported consolidated revenue from operations of Rs 39.84 Cr for Q1 FY27 (quarter ended June 30, 2026), an increase of 16.57% YoY compared to Rs 34.18 Cr in Q1 FY26, though down 34.64% QoQ from Rs 60.96 Cr. Consolidated net profit for the quarter stood at Rs 4.67 Cr, down 6.98% YoY from Rs 5.02 Cr in Q1 FY26 and up 4.66% QoQ from Rs 4.46 Cr. Basic EPS for the quarter was reported at Rs 0.192 compared to Rs 0.217 in the year-ago period. Standalone sales were driven primarily by the domestic market at Rs 25.37 Cr, followed by export markets led by Colombia (Rs 3.51 Cr) and Egypt (Rs 2.54 Cr).

• Consolidated revenue from operations grew 16.57% YoY to Rs 39.84 Cr (3,984.17 Lacs) vs Rs 34.18 Cr in Q1 FY26.
• Consolidated PAT declined 6.98% YoY to Rs 4.67 Cr (466.64 Lacs) vs Rs 5.02 Cr in Q1 FY26.
• Consolidated Basic and Diluted EPS stood at Rs 0.192 versus Rs 0.217 in Q1 FY26.
• Standalone domestic revenue was Rs 25.37 Cr, while top export geographies were Colombia (Rs 3.51 Cr) and Egypt (Rs 2.54 Cr).

Gennex Laboratories reported consolidated revenue from operations of ₹39.84 Cr for Q1 FY27, up 16.6% YoY compared to ₹34.18 Cr in Q1 FY26, but down 34.6% sequentially from ₹60.96 Cr in Q4 FY26. Consolidated net profit for the quarter stood at ₹4.67 Cr, down 7.0% YoY from ₹5.02 Cr, though slightly higher sequentially vs ₹4.46 Cr. Consolidated basic EPS came in at ₹0.192 compared to ₹0.217 in the year-ago quarter. The standalone business contributed revenue of ₹34.68 Cr and net profit of ₹3.96 Cr.

• Consolidated revenue from operations grew 16.6% YoY to ₹39.84 Cr (₹3,984.17 Lakhs) from ₹34.18 Cr in Q1 FY26
• Consolidated PAT fell 7.0% YoY to ₹4.67 Cr (₹466.64 Lakhs) from ₹5.02 Cr in Q1 FY26
• Standalone revenue from operations reached ₹34.68 Cr compared to ₹25.64 Cr in Q1 FY26
• India business generated standalone revenue of ₹25.37 Cr, followed by Colombia at ₹3.51 Cr and Egypt at ₹2.54 Cr
• Consolidated diluted EPS for the quarter was ₹0.192 vs ₹0.206 in Q1 FY26

Gennex Laboratories has scheduled a board meeting for August 14, 2026, to consider and approve its unaudited financial results for the quarter ended June 30, 2026. The company is entering the new fiscal year following a growth phase where FY26 revenue reached Rs 173 Cr compared to Rs 138 Cr in FY25. Investors will be watching to see if the high revenue momentum of Rs 60.96 Cr from the March 2026 quarter continues. The company currently maintains a modest valuation with a P/E of 11.4 and a market capitalization of Rs 240 Cr.

• Board meeting scheduled for August 14, 2026, at 04:00 PM
• Financial results to be considered for the quarter ended June 30, 2026
• Trading window for designated persons has been closed since July 01, 2026
• Company reported TTM revenue of Rs 177 Cr and TTM PAT of Rs 21 Cr